Drug Profile
Research programme: neurodegenerative disorder therapeutics - Axxam/Sanofi
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Axxam
- Developer Axxam; Sanofi
- Class Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Neurodegenerative-disorders in France
- 28 Oct 2021 No recent reports of development identified for research development in Neurodegenerative-disorders in Italy
- 05 Sep 2017 Axxam and Sanofi agree to co-research and develop therapeutics for neurodegenerative disorders